Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 16/20 | 0.85 |
| ▸ | PSMB1 | P20618 | 10/20 | 0.85 |
| ▸ | PSMB2 | P49721 | 10/20 | 0.85 |
| ▸ | PSMB11 | A5LHX3 | 9/20 | 0.85 |
| ▸ | PSMA7 | O14818 | 9/20 | 0.85 |
| ▸ | PSMA1 | P25786 | 9/20 | 0.85 |
| ▸ | PSMA2 | P25787 | 9/20 | 0.85 |
| ▸ | PSMA3 | P25788 | 9/20 | 0.85 |
| ▸ | PSMA4 | P25789 | 9/20 | 0.85 |
| ▸ | PSMB8 | P28062 | 9/20 | 0.85 |
| ▸ | PSMB9 | P28065 | 9/20 | 0.85 |
| ▸ | PSMA5 | P28066 | 9/20 | 0.85 |
| ▸ | PSMB4 | P28070 | 9/20 | 0.85 |
| ▸ | PSMB6 | P28072 | 9/20 | 0.85 |
| ▸ | PSMB10 | P40306 | 9/20 | 0.85 |
| ▸ | PSMB3 | P49720 | 9/20 | 0.85 |
| ▸ | PSMA6 | P60900 | 9/20 | 0.85 |
| ▸ | PSMA8 | Q8TAA3 | 9/20 | 0.85 |
| ▸ | PSMB7 | Q99436 | 9/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydroxysalinosporamide A SCHEMBL8170369 | 1.00 | PSMB5 (0.85) | PSMB5PSMB1PSMB2PSMB11PSMA7 | |
| Hydroxysalinosporamide A SCHEMBL8170234 | 1.00 | PSMB5 (0.85) | PSMB5PSMB1PSMB2PSMB11PSMA7 | |
| Hydroxysalinosporamide A SCHEMBL23266050 | 1.00 | PSMB5 (0.85) | PSMB5PSMB1PSMB2PSMB11PSMA7 | |
| Hydroxysalinosporamide A SCHEMBL8170371 | 1.00 | PSMB5 (0.85) | PSMB5PSMB1PSMB2PSMB11PSMA7 | |
| SCHEMBL6383689 | 0.93 | PSMB5 (0.86) | PSMB5PSMB1PSMB2PSMB11PSMA7 | |
| SCHEMBL8178533 | 0.93 | PSMB5 (0.85) | PSMB5PSMB1PSMB2PSMB11PSMA7 | |
| Fluorosalinosporamide SCHEMBL31187487 | 0.93 | PSMB5 (0.83) | PSMB5PSMB1PSMB2PSMB11PSMA7 | |
| SCHEMBL8178284 | 0.93 | PSMB5 (0.85) | PSMB5PSMB1PSMB2PSMB11PSMA7 | |
| SCHEMBL8183419 | 0.93 | PSMB5 (0.85) | PSMB5PSMB1PSMB2PSMB11PSMA7 | |
| SCHEMBL8126861 | 0.93 | PSMB5 (0.85) | PSMB5PSMB1PSMB2PSMB11PSMA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246990-A1 | PROCESS OF PREPARING (1R, 4R, 5S)-4-(2-CHLOROETHYL)-1-((S)-((S)-CYCLOHEX-2-EN-1-YL)(HYDROXY)METHYL)-5-METHYL-6-OXA-2-AZABICYCLO[3.2.0]HEPTANE-3,7-DIONE(SALINOSPORAMIDE A; MARIZOMIB) | CELGENE INTERNATIONAL II SARL (CH) | 2024-07-25 | — | — | US | claimed |
| EP-4045671-A1 | PROCESS OF PREPARING (1R, 4R, 5S)-4-(2-CHLOROETHYL)-1-((S)-((S)-CYCLOHEX-2-EN-1-YL)(HYDROXY)METHYL)-5-METHYL-6-OXA-2-AZABICYCLO[3.2.0]HEPTANE-3,7-DIONE(SALINOSPORAMIDE A; MARIZOMIB) | Celgene International II Sàrl (CH) | 2022-08-24 | — | — | EP | claimed |
| US-20240246990-A1 | PROCESS OF PREPARING (1R, 4R, 5S)-4-(2-CHLOROETHYL)-1-((S)-((S)-CYCLOHEX-2-EN-1-YL)(HYDROXY)METHYL)-5-METHYL-6-OXA-2-AZABICYCLO[3.2.0]HEPTANE-3,7-DIONE(SALINOSPORAMIDE A; MARIZOMIB) | CELGENE INTERNATIONAL II SARL (CH) | 2024-07-25 | — | — | US | disclosed |
| EP-4045671-A1 | PROCESS OF PREPARING (1R, 4R, 5S)-4-(2-CHLOROETHYL)-1-((S)-((S)-CYCLOHEX-2-EN-1-YL)(HYDROXY)METHYL)-5-METHYL-6-OXA-2-AZABICYCLO[3.2.0]HEPTANE-3,7-DIONE(SALINOSPORAMIDE A; MARIZOMIB) | Celgene International II Sàrl (CH) | 2022-08-24 | — | — | EP | disclosed |
| WO-2021076629-A1 | PROCESS OF PREPARING (1R, 4R, 5S)-4-(2-CHLOROETHYL)-1-((S)-((S)-CYCLOHEX-2-EN-1-YL)(HYDROXY)METHYL)-5-METHYL-6-OXA-2-AZABICYCLO[3.2.0]HEPTANE-3,7-DIONE(SALINOSPORAMIDE A; MARIZOMIB) | CELGENE INTERNATIONAL II SARL (CH) | 2021-04-22 | — | — | WO | disclosed |
| EP-2631237-A2 | Total synthesis of salinosporamide A and analogs thereof | Nereus Pharmaceuticals, Inc. (US) | 2013-08-28 | — | — | EP | disclosed |
| US-8394816-B2 | Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia | TRIPHASE RESEARCH AND DEVELOPMENT I CORP. (CA) | 2013-03-12 | — | — | US | disclosed |
| US-8394816-B2 | Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia | TRIPHASE RESEARCH AND DEVELOPMENT I CORP. (CA) | 2013-03-12 | — | — | US | disclosed |
| US-8389564-B2 | Proteasome inhibitors | TRIPHASE RESEARCH AND DEVELOPMENT I CORP. (CA) | 2013-03-05 | — | — | US | disclosed |
| US-20130012720-A1 | TOTAL SYNTHESIS OF SALINOSPORAMIDE A AND ANALOGS THEREOF | NEREUS PHAMACEUTICALS, INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-8314251-B2 | Total synthesis of salinosporamide A and analogs thereof | NEREUS PHARMACEUTICALS, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-20080070969-A1 | [3.2.0] HETEROCYCLIC COMPOUNDS AND METHODS OF USING THE SAME | NEREUS PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| US-20080070969-A1 | [3.2.0] HETEROCYCLIC COMPOUNDS AND METHODS OF USING THE SAME | NEREUS PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| US-20070249693-A1 | deprotecting, aldol condensations, cleaving double bonds, deesterifying, alcoholization, oxidation with organometallic, lactonization | NEREUS PHARMACEUTICALS, INC. (US) | 2007-10-25 | — | — | US | disclosed |
| US-20070249693-A1 | deprotecting, aldol condensations, cleaving double bonds, deesterifying, alcoholization, oxidation with organometallic, lactonization | NEREUS PHARMACEUTICALS, INC. (US) | 2007-10-25 | — | — | US | disclosed |
| WO-2007117591-A2 | TOTAL SYNTHESIS OF SALINOSPORAMIDE A AND ANALOGS THEREOF | NEREUS PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
| US-7276530-B2 | [3.2.0] Heterocyclic compounds and methods of using the same | NEREUS PHARMACEUTICALS, INC. (US) | 2007-10-02 | — | — | US | disclosed |
| US-7276530-B2 | [3.2.0] Heterocyclic compounds and methods of using the same | NEREUS PHARMACEUTICALS, INC. (US) | 2007-10-02 | — | — | US | disclosed |
| US-20070004676-A1 | Methods of using [3.2.0] heterocyclic compounds and analogs thereof | TRIPHASE RESEARCH AND DEVELOPMENT I CORP. (CA) | 2007-01-04 | — | — | US | disclosed |
| US-20070004676-A1 | Methods of using [3.2.0] heterocyclic compounds and analogs thereof | TRIPHASE RESEARCH AND DEVELOPMENT I CORP. (CA) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012720-A1 | TOTAL SYNTHESIS OF SALINOSPORAMIDE A AND ANALOGS THEREOF | ERG28, CYP51A1, EIF4A2 | PSMB5 2700/4885PSMB1 3493/4885PSMB2 2769/4885 |
| US-20240246990-A1 | PROCESS OF PREPARING (1R, 4R, 5S)-4-(2-CHLOROETHYL)-1-((S)-((S)-CYCLOHEX-2-EN-1-YL)(HYDROXY)METHYL)-5-METHYL-6-OXA-2-AZABICYCLO[3.2.0]HEPTANE-3,7-DIONE(SALINOSPORAMIDE A; MARIZOMIB) | PSMA5, EPOR, CYP8B1 | PSMB5 4/4885PSMB1 41/4885PSMB2 38/4885 |
| US-20080070969-A1 | [3.2.0] HETEROCYCLIC COMPOUNDS AND METHODS OF USING THE SAME | HPGDS, LTC4S, SDHA | PSMB5 3863/4885PSMB1 4436/4885PSMB2 3865/4885 |
| US-20070249693-A1 | deprotecting, aldol condensations, cleaving double bonds, deesterifying, alcoholization, oxidation with organometallic, lactonization | ADH1C, ADH1A, ADH5 | PSMB5 2681/4885PSMB1 3821/4885PSMB2 3721/4885 |
| US-20070004676-A1 | Methods of using [3.2.0] heterocyclic compounds and analogs thereof | SDHA, HCCS, CYP11B2 | PSMB5 2651/4885PSMB1 3768/4885PSMB2 2638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.